Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04318327 · ClinicalTrials.gov registry record · Phase 1
BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
NCT04318327 is a Phase 1 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 96 participants.
The verdict
NCT04318327, a Phase 1 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
Study Summary
This was a first-in-human study to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous T cells genetically engineered with a novel B-cell Maturation Antigen (BCMA)-specific chimeric antigen receptor (CAR) and manufactured with a new process. CAR-T cells were investigated as a single agent in multiple myeloma
Interventions
- BIOLOGICAL PHE885
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2020-07-23 |
| Est. Completion | 2025-04-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04318327
The ClinicalTrials.gov registry entry for NCT04318327 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PHE885 is the first listed.
NCT04318327 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04318327 about?
NCT04318327 is a clinical study titled "BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma". This was a first-in-human study to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous T cells genetically engineered with a novel B-cell Maturation Antigen (BCMA)-specific chimeric antigen receptor (CAR) and manufactured with a new process. CAR-T cells were investigate...
What is the current status of trial NCT04318327?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2020-07-23. Estimated completion is 2025-04-29.
What interventions are being tested in trial NCT04318327?
The interventions under investigation include: PHE885 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04318327?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.